Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Firazyr - withdrawal of application for variation to marketing authorisation

Firazyr - withdrawal of application for variation to marketing authorisation

Application withdrawn

The application for a change to this medicine's authorisation has been withdrawn.

icatibant
Post-authorisationHuman

Page contents

  • Overview
  • Key facts
  • Documents
  • Related information on withdrawals
  • News on Firazyr
  • More information on Firazyr

Overview

On 14 February 2014, Shire Orphan Therapies GmbH officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application to extend the use of Firazyr in the treatment of angioedema caused by medicines called angiotensin-converting enzyme inhibitors.

Firazyr is a solution for injection that contains the active substance icatibant. It has been authorised since July 2008 for treating the symptoms of attacks of hereditary angioedema in adults. Patients with angioedema have attacks of swelling that can occur anywhere in the body, such as in the face or limbs, or around the gut, causing discomfort and pain. Hereditary angioedema is angioedema caused by abnormalities in the genes responsible for the production of a protein called 'C1 esterase inhibitor'. Firazyr is used when these genetic abnormalities result in low levels of functional C1 esterase inhibitor.

Firazyr was designated an 'orphan medicine' (a medicine to be used in rare diseases) on 17 February 2003 for the treatment of angioedema.

Firazyr was also expected to be used for the treatment of angioedema caused by medicines called angiotensin-converting enzyme inhibitors (ACE-I).

In angioedema caused by ACE-I, Firazyr is expected to work in the same way as it does in its existing indication.

Patients with angioedema have high levels of a substance called bradykinin, which is involved in causing inflammation and swelling. The active substance in Firazyr, icatibant, blocks the receptors that bradykinin normally attaches itself to. This blocks the activity of bradykinin, helping to relieve the symptoms of the disease.

The applicant presented data from one main study involving 27 patients with an angioedema attack caused by ACE-I. In the study, patients were given either Firazyr or standard therapy with two medicines called a corticosteroid and an antihistamine. The main measure of effectiveness was the time needed for the patient's symptoms to resolve.

The application was withdrawn after the CHMP had evaluated the initial documentation provided by the company and formulated lists of questions. The CHMP was assessing the company's responses to the questions at the time of the withdrawal.

Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Firazyr could not have been approved for the treatment of ACE-I induced angioedema.

Following an inspection of one of the study sites, the CHMP had concerns over the way the study was conducted. In particular, important study documentation confirming which treatment each patient received was missing. In addition, the CHMP was concerned that the investigators may have become aware of which treatment patients received, which could have affected the reliability of the data. Finally, some of the data included in the results had not been collected in accordance with the study design.

Therefore, at the time of the withdrawal, the results of the study were not considered to be reliable and the CHMP concluded that the medicine could not have been approved on the basis of the data presented by the company.

In its letter notifying the Agency of the withdrawal of application, the company stated that its decision to withdraw the application was based on the CHMP's view that the data provided so far were not sufficient to address the CHMP's concerns and that more data would be needed.

The company informed the CHMP that the currently ongoing clinical study with Firazyr in ACE-I induced angioedema will continue.

If you are in a clinical trial and need more information about your treatment, contact the doctor who is giving it to you.

There are no consequences on the use of Firazyr in its authorised indication.

Questions and answers on the Withdrawal of the application for a change to the marketing authorisation for Firazyr (icatibant)

Reference Number: EMA/95900/2014

English (EN) (112.41 KB - PDF)

First published: 21/02/2014Last updated: 21/02/2014
View

Key facts

Name of medicine
Firazyr
EMA product number
EMEA/H/C/000899
Active substance
icatibant
International non-proprietary name (INN) or common name
icatibant
Therapeutic area (MeSH)
Angioedemas, Hereditary
Anatomical therapeutical chemical (ATC) code
B06AC02
Marketing authorisation holder
Takeda Pharmaceuticals International AG
Date of issue of marketing authorisation valid throughout the European Union
11/07/2008
Date of withdrawal
14/02/2014

Documents

Withdrawal letter: Firazyr (icatibant)

Reference Number: EMA/95900/2014

English (EN) (152.75 KB - PDF)

First published: 21/02/2014Last updated: 21/02/2014
View

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

News on Firazyr

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11 to 14 September 2017
15/09/2017
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 February 2014
21/02/2014

More information on Firazyr

  • Firazyr
This page was last updated on 21/02/2014

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union